Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Onconova Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer.  The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways important for cancer cell proliferation.  Onconova's product candidates include narazaciclib and rigosertib.

Metric
Company Name	Onconova Therapeutics, Inc.	Axsome Therapeutics, Inc.
Symbol	ONTX	AXSM
MSH ID	COM:ONCONOVA	COM:AXSOME
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	16	569
Website	onconova.com	axsome.com
LinkedIn
Founders

Metric
Market Cap	20.90M	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue		270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit		237.70M
EBITDA		-176.07M
Operating Income		-182.91M
Net Income		-239.24M
EPS		-5.27
Diluted EPS		-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.90
Operating Profit Margin		-0.86
EBITDA Margin		-0.65
Net Profit Margin		-0.88
Return on Equity		-1.12
Return on Assets		-0.41
Return on Capital Employed		-0.52

COM:ONCONOVA

Onconova Therapeutics, Inc.

Last Close

1.00

02/04 20:00

Market Cap

20.90M

Beta: -

Volume Today

1.25M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-20.81
P/B Ratio		16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		16.65
EV Multiple		-11.57

Metric
Days Sales Outstanding		128.09
Days Payables Outstanding		506.28
Days Inventory Outstanding		229.29
Operating Cycle		383.54
Cash Conversion Cycle		-229.81
Asset Turnover		0.53

Metric
Operating Cash Flow		-145.08M
Free Cash Flow		-145.66M
Cash Flow to Debt		-0.81
Operating Cash Flow/Sales		-0.54
Free Cash Flow Yield		-0.03

Metric
Cash & Equivalents		386.19M
Accounts Receivable		-57.12M
Inventory		15.13M
Goodwill		12.04M
Debt to Capitalization		0.65
Debt to Assets		0.31
Current Ratio		4.46
Quick Ratio		3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.24
R&D to Revenue		0.37
SG&A to Revenue		0.44